least common multiple of T and R [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2021-05-26 02:23 (1486 d 03:56 ago) – Posting: # 22367
Views: 3,249

Hi Vishal,

❝ we are designing the fixed dose combination Immediate release test formulation(A+B) […] 325 mg(B) […] Note than RLD (B) available in EU market in 500 mg strength, 325 mg strength not available as RLD.

  1. There are no reference-listed drugs in Europe.
  2. Did you bother reading the section I linked in my previous post? BE means always comparing BA of the same doses. An adjustment$$\small{\frac{f_\textrm{T}}{f_\textrm{R}}=\frac{AUC_\textrm{T}\,\cdot D_\textrm{R}}{AUC_\textrm{R}\,\cdot D_\textrm{T}}}$$would not be acceptable.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,676 registered users;
45 visitors (0 registered, 45 guests [including 11 identified bots]).
Forum time: 06:20 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5